Remodulin (including Remunity Pump) sales rose 17% year over year to $134.5 million due to higher volume growth in the United States. Sales of Orenitram rose 28% year over year to $107.8 million ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...

We continue to see strong referral and start trends for Remodulin. In January, our partner, DEKA, received FDA clearance for the new RemUnity Pro pump. RemUnity Pro is the next generation in ...

Right heart failure occurs when the heart is too weak to pump adequate blood supply to the lungs ... Label: Ventavis- iloprost solution. DailyMed. Label: Remodulin- treprostinil injection, solution ...

The growth in Remodulin revenues resulted from an increase in U.S. Remodulin revenues and, to a lesser extent, an increase in international Remodulin revenues, driven, in both cases, by an ...

The increase in share-based compensation expense for the quarter ended December 31, 2024, as compared to the same period in 2023, was primarily due to: (1) an increase in stock option expense due ...

The preparations were stored in i.v. infusion pumps over a 48-hour period at 40 °C and 75% relative humidity and passed through an i.v. drug delivery system. The duration of storage was based on ...

Epoprostenol sodium is delivered by continuous i.v. administration using an ambulatory infusion pump through an indwelling, surgically implanted central line. Treprostinil sodium, which has a ...